AlzeCure Pharma logo

Loading..
Svenska
Svenska
  • About us
    About us
      • AlzeCure Pharma in brief
      • Mission, vision & strategy
      • A word from the CEO
      • Organization
        • Management team
        • Board of directors
        • Founders
        • Scientific advisors
        • Collaborations and Partnership
      • History
      • Career
        • Open positions
  • Research & development
    Research & development
      • Project portfolio
      • NeuroRestore
      • Alzstatin
      • Alzheimer’s disease
      • Painless
        • ACD440
        • TrkA-NAM
      • Pain
      • Small molecules
      • Publications
  • Governance
    Governance
      • Corporate Governance Reports
      • General meeting
        • General meetings
      • Nomination Committee
      • Board of directors
      • Management team
      • Remuneration
      • Auditors
      • Articles of association
  • Investors
    Investors
      • Capital Markets Day 2023
      • AlzeCure Pharma on First North Premier Growth Market
        • Certified Adviser
      • Prospectuses
        • Rights Issue December 2022
        • Rights Issue 2022
        • Listing prospectus 2018
      • The share
        • Trading information
        • Sharecapital development
        • Dividend policy
        • Ownership structure
        • Insiders
        • Analyst Coverage
      • Financial reports
      • Financial calendar
      • Presentations and Interviews
      • Subscribe
      • Contact
  • Media
    Media
      • Press releases
      • Presentations and Interviews
      • Video gallery
      • Image bank
        • Board of directors
        • Management
        • Founders
        • Logotype
      • Financial calendar
      • Subscribe
      • Contact
  • Contact
    Contact
      • Office
      • Investors
      • Media

Media

Mikael Widell
Mikael Widell
Head of Communications and IR
mikael.widell@alzecurepharma.com
+46 703 11 99 60
Share
  • Contact
    • Office
    • Investors
    • Media
About us
  • AlzeCure Pharma in brief
  • Mission, Vision & Strategy
  • A word from the CEO
  • Organization
  • Career
  • History
Research & development
  • Project portfolio
  • NeuroRestore
  • Alzstatin
  • Alzheimer’s disease
  • Painless
  • Pain
  • Small molecules
  • Publications
Governance
  • Corporate Governance Reports
  • General meeting
  • Nomination Committee
  • Board of directors
  • Management team
  • Remuneration
  • Auditors
  • Articles of association
Investors
  • Capital Markets Day 2023
  • AlzeCure Pharma on First North Premier Growth Market
  • The share
  • Financial reports
  • Financial calendar
  • Presentations and Interviews
  • Subscribe
  • Contact
Media
  • Press releases
  • Presentations and Interviews
  • Video gallery
  • Image bank
  • Financial calendar
  • Subscribe
  • Contact
Contact
  • Office
  • Investors
  • Media

AlzeCure Pharma AB, Hälsovägen 7,  SE-141 57 Huddinge, Sweden. Registration number: 559094-8302.

  • Follow us on LinkedIn
  • About cookies
  • Privacy policy for Alzecure Pharma